Literature DB >> 17879418

Clindamycin-induced acute cholestatic hepatitis.

Cem Aygun1, Orhan Kocaman, Yesim Gurbuz, Omer Senturk, Sadettin Hulagu.   

Abstract

We report a case of acute hepatotoxicity in a 42-year-old woman after administration of clindamycin for a dental infection. After 6 d of treatment, she had fatigue, nausea, vomiting, anorexia, pruritus and jaundice. Her laboratory analysis showed alanine aminotransferase (ALT), 1795 IU/L (normal range 0-40); aspartate aminotransferase (AST), 1337 IU/L (normal range 5-34); alkaline phosphatase (ALP), 339 IU/L (normal range 40-150); gamma-glutamyl transpeptidase (GGT), 148 IU/L (normal range 9-64 IU/L); total bilirubin, 4.1 mg/dL; direct bilirubin, 2.9 mg/dL and prothrombin time (PT), 13.5 s, with international normalized ratio (INR), 1.04. She was hospitalized, with immediate drug discontinuation. Her liver biopsy specimen showed mixed-type (both hepatocellular and cholestatic) hepatic injury, compatible with a diagnosis of drug-induced hepatitis. An objective causality assessment using the Naranjo probability scale suggested that clindamycin was the probable cause of the acute hepatitis. In susceptible individuals, clindamycin use may lead to acute mixed-type liver toxicity. Complete recovery may be possible if the drug is discontinued before severe liver injury is established.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17879418      PMCID: PMC4171338          DOI: 10.3748/wjg.v13.i40.5408

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  8 in total

1.  Drug-Induced Liver Disease.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-12

Review 2.  Cross-reactivity with drugs at the T cell level.

Authors:  Jan P H Depta; Werner J Pichler
Journal:  Curr Opin Allergy Clin Immunol       Date:  2003-08

Review 3.  Drug-induced hepatotoxicity.

Authors:  William M Lee
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

4.  Pharmacokinetic studies of clindamycin hydrochloride in humans.

Authors:  R M DeHaan; C M Metzler; D Schellenberg; W D VandenBosch; E L Masson
Journal:  Int J Clin Pharmacol       Date:  1972-06

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation.

Authors:  D Mazur; B S Schug; G Evers; V Larsimont; H Fieger-Büschges; W Gimbel; A Keilbach-Bermann; H H Blume
Journal:  Int J Clin Pharmacol Ther       Date:  1999-08       Impact factor: 1.366

Review 7.  Delayed drug hypersensitivity reactions.

Authors:  Werner J Pichler
Journal:  Ann Intern Med       Date:  2003-10-21       Impact factor: 25.391

8.  Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole.

Authors:  I Altraif; L Lilly; I R Wanless; J Heathcote
Journal:  Am J Gastroenterol       Date:  1994-08       Impact factor: 10.864

  8 in total
  6 in total

Review 1.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

2.  A challenge for diagnosing acute liver injury with concomitant/sequential exposure to multiple drugs: can causality assessment scales be utilized to identify the offending drug?

Authors:  Roxanne Lim; Hassan Choudry; Kim Conner; Wikrom Karnsakul
Journal:  Case Rep Pediatr       Date:  2014-11-24

3.  Oral clindamycin causing acute cholestatic hepatitis without ductopenia: a brief review of idiosyncratic drug-induced liver injury and a case report.

Authors:  Harsha Moole; Zohair Ahmed; Nibha Saxena; Srinivas R Puli; Sonu Dhillon
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-10-19

4.  Characterizing the network of drugs and their affected metabolic subpathways.

Authors:  Chunquan Li; Desi Shang; Yan Wang; Jing Li; Junwei Han; Shuyuan Wang; Qianlan Yao; Yingying Wang; Yunpeng Zhang; Chunlong Zhang; Yanjun Xu; Wei Jiang; Xia Li
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

5.  Hepatotoxicity due to Clindamycin in Combination with Acetaminophen in a 62-Year-Old African American Female: A Case Report and Review of the Literature.

Authors:  Jerome Okudo; Nwabundo Anusim
Journal:  Case Reports Hepatol       Date:  2016-07-04

6.  Sarcocystis sp. encephalomyelitis in a cat.

Authors:  Tricia M Bisby; Patricia J Holman; George A Pitoc; Rebecca A Packer; Craig A Thompson; Rose E Raskin
Journal:  Vet Clin Pathol       Date:  2009-06-22       Impact factor: 1.180

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.